ReviewACS nanoscience Au2026
Breaking Through the Barrier: Nanoparticle-Driven MRI Strategies for Diagnosis and Therapy of Pancreatic Cancer.
Review in ACS nanoscience Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer due to late diagnosis, limited biomarkers, and a dense stromal microenvironment that hinder imaging and therapy. Magnetic resonance imaging (MRI) offers high soft-tissue resolution but lacks molecular sensitivity and specificity when applied to PDAC. Advanced MRI methods such as diffusion-weighted imaging (DWI), hyperpolarized MRI, MR elastography (MRE), and dynamic contrast-enhanced MRI (DCE-MRI) have expanded the ability to characterize tumor microstructure, metabolism, stiffness, and perfusion, offering valuable functional insights. Nanoparticle-based contrast agents are emerging as promising tools to overcome these limitations by improving sensitivity, targeting tumor biomarkers, and enabling theranostic applications. This review explores the frontiers of nanoparticle-enhanced MRI in the context of PDAC. Recent studies show that superparamagnetic iron oxide nanoparticles (SPIONs) enhance T2-weighted MRI contrast and detect small PDAC lesions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.